Long term results of hepatic resection or orthotopic liver transplantation in patients with liver metastases from gastrointestinal neuroendocrine tumors

被引:3
作者
Pasqual, Enrico Maria [1 ]
Bertozzi, Serena [1 ]
Londero, Ambrogio P. [2 ]
Bacchetti, Stefano [1 ]
Lorenzin, Dario [1 ]
Pasqualucci, Alberto [3 ]
Moccheggiani, Federico [4 ]
Federici, Alen [4 ]
Vivaverlli, Marco [4 ]
Risaliti, Andrea [1 ]
机构
[1] Univ Udine DISM DSMB, Santa Maria della Misericordia Univ Hosp, Dept Surg, I-33100 Udine, Italy
[2] S Polo Hosp, Unit Obstet & Gynecol, I-34074 Monfalcone, Italy
[3] Univ Perugia, Dept Anaesthesiol, I-06123 Perugia, Italy
[4] Marche Polytech Univ, G Salesi Univ Hosp, Dept Surg, Osped Riuniti Umberto 1,FM Lancisi, I-60123 Ancona, Italy
关键词
gastroenteropancreatic neuroendocrine tumors; liver metastases; orthotopic liver transplantation; hepatic resection; overall survival; CARCINOID-TUMORS; SURGICAL-MANAGEMENT; SURGERY; SURVIVAL; THERAPIES; NEOPLASMS; DIAGNOSIS; DATABASE; TRACT;
D O I
10.3892/ol.2016.5045
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Hepatic metastases are one of the most important prognostic factors for survival among patients affected by gastrointestinal neuroendocrine tumors (NETs). The present study aims to evaluate the impact of surgery, including hepatic resection or orthotopic liver transplantation (OLT), on the outcome of patients affected by hepatic metastases from NETs, in terms of overall survival (OS). In this multicentric retrospective study, data was collected on 26 patients, who underwent surgery for hepatic metastases from NETs in two Italian University Clinics between January 1990 and December 2012; of which, 22 patients underwent hepatic resective surgery and 4 patients OLT. Hepatic metastases were synchronous in the 53.8% of cases and metachronous in the 46.2% of cases. The median number of resected hepatic metastases was 3. Surgical radicalness (R0) was reached in the 84.6% of cases. In total, 57.7% of patients had a recurrence, 66.7% of which were intra- and 33.3% extra-hepatic. The OS of patients that underwent hepatic resections and OLT was 44.9% [95% confidence interval (CI95), 26.0-77.7%] and 50% (CI95, 12.5-100.0%) at 5 years, respectively. Although the data regarding the survival of patients receiving surgery for hepatic metastases from NETs are encouraging, randomized clinical trials are necessary to more adequately evaluate the effect of surgery on survival of this group of patients.
引用
收藏
页码:3563 / 3570
页数:8
相关论文
共 43 条
  • [1] Right lobe living related graft loss due to intrahepatic multiple arterio-portal fistulas
    Adani, GL
    Baccarani, U
    Risaliti, A
    Sainz-Barriga, M
    Lorenzin, D
    Bresadola, F
    [J]. TRANSPLANTATION PROCEEDINGS, 2004, 36 (09) : 2733 - 2735
  • [2] Therapeutic strategies for advanced neuroendocrine carcinomas of jejunum/ileum and pancreatic origin
    Auernhammer, Christoph J.
    Goeke, Burkhard
    [J]. GUT, 2011, 60 (07) : 1009 - 1021
  • [3] Surgical Treatment and Survival in Patients with Liver Metastases from Neuroendocrine Tumors: A Meta-Analysis of Observational Studies
    Bacchetti, Stefano
    Bertozzi, Serena
    Londero, Ambrogio P.
    Uzzau, Alessandro
    Pasqual, Enrico Maria
    [J]. INTERNATIONAL JOURNAL OF HEPATOLOGY, 2013, 2013
  • [4] Liver transplantation and neuroendocrine tumors: lessons from a single centre experience and from the literature review
    Bonaccorsi-Riani, Eliano
    Apestegui, Carlos
    Jouret-Mourin, Anne
    Sempoux, Christine
    Goffette, Pierre
    Ciccarelli, Olga
    Borbath, Ivan
    Hubert, Catherine
    Gigot, Jean Francois
    Hassoun, Ziad
    Lerut, Jan
    [J]. TRANSPLANT INTERNATIONAL, 2010, 23 (07) : 668 - 678
  • [5] Hepatic neuroendocrine metastases: Does intervention alter outcomes?
    Chamberlain, RS
    Canes, D
    Brown, KT
    Saltz, L
    Jarnagin, W
    Fong, YM
    Blumgart, LH
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2000, 190 (04) : 432 - 445
  • [6] Histologic grade is correlated with outcome after resection of hepatic neuroendocrine neoplasms
    Cho, Clifford S.
    Labow, Daniel M.
    Tang, Laura
    Klimstra, David S.
    Loeffler, Agnes G.
    Leverson, Glen E.
    Fong, Yuman
    Jarnagin, William R.
    D'Angelica, Michael I.
    Weber, Sharon M.
    Blumgart, Leslie H.
    DeMatteo, Ronald R.
    [J]. CANCER, 2008, 113 (01) : 126 - 134
  • [7] Resection versus transplantation for liver metastases from neuroendocrine tumors
    Coppa, J
    Pulvirenti, A
    Schiavo, M
    Romito, R
    Collini, P
    Di Bartolomeo, M
    Fabbri, A
    Regalia, E
    Mazzaferro, V
    [J]. TRANSPLANTATION PROCEEDINGS, 2001, 33 (1-2) : 1537 - 1539
  • [8] New drugs in neuroendocrine tumors: rising of new therapeutic philosophies?
    Eriksson, Barbro
    [J]. CURRENT OPINION IN ONCOLOGY, 2010, 22 (04) : 381 - 386
  • [9] Fahey TJ, 2003, SURGERY, V134, P1063
  • [10] Treatment of liver metastases in patients with neuroendocrine tumors
    Frilling, A
    Rogiers, X
    Malago, M
    Liedke, OM
    Kaun, M
    Broelsch, CE
    [J]. LANGENBECKS ARCHIVES OF SURGERY, 1998, 383 (01) : 62 - 70